Lucid Diligence Brief: Candel Therapeutics $100m funding for CAN-2409 in localized prostate cancer
Lucid Diligence Brief: Candel Therapeutics $100m funding for CAN-2409 in…
Cell and Gene Therapy Today—February 19, 2026
This week's update in gene and cell therapy covers notable developments…
Rare Diseases Today—February 12, 2026
This week's Rare diseases update covers regulatory actions, clinical…
Lucid Diligence Brief: Eli Lilly Pipeline Rationalization
Lucid Diligence Brief: Eli Lilly Pipeline Rationalization Professional…
Cell and Gene Therapy Today—February 5, 2026
This week's Cell and Gene Therapy updatehighlights key regulatory actions,…
Neuroscience Today—February 4, 2026
This week's Neuroscience update summarizes key developments in clinical…
Lucid Diligence Brief: ZipBio licenses its AI-designed GA AAV program to MeiraGTx
Lucid Diligence Brief: ZipBio licenses its AI-designed GA AAV program to…
Lucid Diligence Brief: Ultragenyx UX111 BLA resubmission
Lucid Diligence Brief: Ultragenyx UX111 BLA resubmission Professional audiences…
Lucid Diligence Brief: Seamless Therapeutics and Lilly enter gene-writing pact in hearing loss
Lucid Diligence Brief: Seamless Therapeutics and Lilly enter gene-writing pact…
Cell and Gene Therapy Today—January 22, 2026
This week’s updates highlight significant advancements in gene and cell…
Rare Disease Today—January 22, 2026
This week's updates focus on significant regulatory approvals, orphan drug…
Lucid Diligence Brief: Ocugen preliminary Phase 2 data in geographic atrophy
Lucid Diligence Brief: Ocugen preliminary Phase 2 data in geographic atrophy…